FDA Accepts Dapagliflozin Application from Centaur Pharmaceuticals
The FDA has accepted the application ANDA220679 for dapagliflozin from Centaur Pharmaceuticals.
Therapeutic Area
Therapeutic area intelligence for SGLT2 Inhibitor with 22 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.